cramer stock picks


There's no need to worry yet.   But investors should start keeping an eye out for bears.   Let me explain…   Bear markets start with three common conditions…   1.   A sudden, sharp rise in interest rates.     2.   A peak in margin debt (the amount of money that investors borrow to buy stocks).     3.   A dip in the S&P 500 monthly chart to below its 20-month exponential moving average (EMA). I wrote about this in September 2015, when it looked like stocks were rolling over into a bear market. These conditions don't always trigger a bear market. But a bear market has never started without these three things happening.

cramer stock picks: Diamondrock Hospitality Company(DRH)


Advisors’ Opinion:

  • [By Monica Gerson]

    DiamondRock Hospitality Company (NYSE: DRH) is projected to post its quarterly earnings at $0.18 per share on revenue of $218.42 million.

    Weyerhaeuser Co (NYSE: WY) is expected to report its quarterly earnings at $0.20 per share.

cramer stock picks: Vuzix Corporation(VUZI)

Advisors’ Opinion:

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.


    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.


    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update. Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million. The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62. Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold. Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split. Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period. AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016. Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By William Patalon III]

    Vuzix Corp. (Nasdaq: VUZI) – the “augmented reality” company whose shares more than doubled following our September 2015 recommendation – said that its new “smart glasses” were just honored with a “Wearable Device of the Year” award.

cramer stock picks: Salesforce.com Inc(CRM)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cloud-software leader Salesforce (CRM) – my Top Pick for 2017 among large cap technology stocks — remains well positioned to reap the benefits of the transition away from on-premises solutions.

  • [By Chris Lange]

    Salesforce.com, Inc. (NYSE: CRM) reported fiscal third-quarter financial results after markets closed last Thursday. Although Salesforce is competing with Oracle, the former outperformed this week as a result of strong earnings. These strong earnings may feed the fire for a potential acquisition and analysts are hiking their price targets.

  • [By Craig Jones]

    Jon Najarian spoke on CNBC's Fast Money Halftime Report about bullish options activity in Salesforce.com, inc. (NYSE: CRM) and Apple Inc. (NASDAQ: AAPL).

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Western Digital (WDC) , Twilio (TWLO) , Adient (ADNT) , Salesforce.com (CRM) , AT&T (T) and Verizon (VZ) .

cramer stock picks: Unilever PLC(UL)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    For his “Executive Decision” segment, Cramer sat down with Paul Polman, CEO of Unilever (UL) , home to such brands as Dove soaps and shampoos, Lipton tea, Hellmann’s mayonnaise and Vaseline, among dozens of others. On Feb. 17, Unilever rejected a hostile takeover bid from Kraft Heinz (KHC) and vowed to bring out more value as a standalone company.

  • [By WWW.THESTREET.COM]

    GLP’s customers include Walmart (WMT) , Unilever (UL) , JD.com (JD) , Adidas (ADDYY) , Estee Lauder (EL) and L’Oreal (LRLCY) .

    The S$3.38 offer price represents 81% premium over its 12-month volume weighted average price and a 25% premium over its last full trading day before the announcement.

  • [By Benzinga News Desk]

    Unilever PLC (NYSE: UL) said it would divest its 145-year-old margarine and spreads business, part of a broad restructuring in the wake of a spurned takeover approach by Kraft Heinz Co. (NASDAQ: KHC): Link

  • [By Lisa Levin]

    Non-cyclical consumer goods & services shares climbed by 1.13 percent in trading on Friday. Meanwhile, top gainers in the sector included Unilever plc (ADR) (NYSE: UL), and Grand Canyon Education Inc (NASDAQ: LOPE).

cramer stock picks: Insys Therapeutics, Inc.(INSY)

Advisors’ Opinion:

  • [By Keith Speights]

    Insys Therapeutics (NASDAQ:INSY) already won U.S. regulatory approval fordronabinol solution Syndros in treatingchemotherapy-induced nausea and vomiting (CINV) and anorexia in patients with AIDS. The company is preparing to launch Syndros soon.

  • [By Keith Speights]

    There are plenty of reasons for investors to like three marijuana stocks in particular — GW Pharmaceuticals (NASDAQ:GWPH), Insys Therapeutics (NASDAQ:INSY), and Aphria (NASDAQOTH:APHQF). In fact, there are at least 661 million reasons. That’s the amount of cash in U.S. dollars that the three companies have combined. Here’s why the cash stockpiles held by GW, Insys, and Apria are important.

  • [By William Patalon III]

    Insys Therapeutics Inc. (NASDAQ: INSY) – our “War on Pain” biotech play – has given us a profit of more than 16% since we recommended the stock just two weeks ago.

  • [By Lisa Levin]

    In trading on Thursday, healthcare shares fell by 0.20 percent. Meanwhile, top losers in the sector included Horizon Pharma PLC (NASDAQ: HZNP), down 20 percent, and Insys Therapeutics Inc (NASDAQ: INSY), down 17 percent.

  • [By Sean Williams]

    Shares of Insys Therapeutics (NASDAQ:INSY), a biopharmaceutical company that develops medicines to treat pain and other supportive-care products, tumbled by as much as 11% during Wednesdays trading session before recovering to finish lower by less than 2%. The reason for the volatile trading can probably be traced to carryover from the company’s first-quarter earnings release before the opening bell on Tuesday.